Data Presented at ASCO Shows Promising 11.7 Month Median Overall Survival in Second-Line NSCLC Patients Treated With Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab

Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer

Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting

Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab

Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine's Bavituximab in Solid Tumor Therapy

Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting

Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments

Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013

Peregrine Announces Participation at Upcoming Investor Conferences

Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process Parameters That Lead to Consistent Product Quality at IBC'S Biopharmaceutical Development and Production Conference